Obesity rates RGAs obesity rate projections for the US non-diabetic population in 20 years (2045) are shown below, both for the baseline scenario (without the medications) and the central scenario (with the medications): For ages 20-90, the model estimates an approximate reduction in obesity prevalence of about 12% for central assumptions relative to the baseline scenario
While the efficacy of herbal GLP-1 patches is doubtful and GLP-1 drug patches are still under trial, this delivery system through skin is said to have some potential benefits like 6 : Note: The benefits mentioned above are only theoretical as there are no GLP-1 patches which are FDA approved
Obesity is a major risk factor for chronic diseases, including diabetes, cardiovascular disease, and certain cancers.[28, 29] Globally, overweight and obesity have doubled in prevalence since 1980 and are estimated to contribute to more than $700 billion in annual healthcare costs.[28, 30] As evidence has mounted for the weight loss effectiveness of GLP-1RAs, their use has grown accordingly
Therefore, real-world evidence provides greater understanding of the effects of these therapeutic options on the population in a real-world setting